• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合酶:抗病毒方案中的关键酶概述。

The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario.

机构信息

Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA) Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.

出版信息

Int J Mol Sci. 2023 Jul 29;24(15):12187. doi: 10.3390/ijms241512187.

DOI:10.3390/ijms241512187
PMID:37569561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10419282/
Abstract

Integration of a desossiribonucleic acid (DNA) copy of the viral ribonucleic acid (RNA) into host genomes is a fundamental step in the replication cycle of all retroviruses. The highly conserved virus-encoded Integrase enzyme (IN; EC 2.7.7.49) catalyzes such a process by means of two consecutive reactions named 3'-processing (3-P) and strand transfer (ST). The Authors report and discuss the major discoveries and advances which mainly contributed to the development of Human Immunodeficiency Virus (HIV) -IN targeted inhibitors for therapeutic applications. All the knowledge accumulated over the years continues to serve as a valuable resource for the design and development of effective antiretroviral drugs.

摘要

整合病毒核糖核酸(RNA)的去氧核糖核酸(DNA)拷贝到宿主基因组中是所有逆转录病毒复制周期的一个基本步骤。高度保守的病毒编码整合酶(IN;EC 2.7.7.49)通过两种连续的反应(分别命名为 3’-加工(3-P)和链转移(ST))催化这一过程。作者报告并讨论了主要的发现和进展,这些发现和进展主要促成了针对治疗应用的人类免疫缺陷病毒(HIV)-IN 靶向抑制剂的开发。多年来积累的所有知识继续为设计和开发有效的抗逆转录病毒药物提供宝贵的资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9594eb6d4ab0/ijms-24-12187-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/8f6d13ddff81/ijms-24-12187-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0e39fe4d7532/ijms-24-12187-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/cc9218802930/ijms-24-12187-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/33018e1ea9b2/ijms-24-12187-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/6ce4a33ded35/ijms-24-12187-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9ceee04b962e/ijms-24-12187-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/5b1d44eda256/ijms-24-12187-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0890d5d36248/ijms-24-12187-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/6bb781cad7a9/ijms-24-12187-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9a6e758e1dd0/ijms-24-12187-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/7a1c09ae7c88/ijms-24-12187-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0472d42eb3bd/ijms-24-12187-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/78ffdd325fa3/ijms-24-12187-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/7e98c5eee41c/ijms-24-12187-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/bcd7a20d36a4/ijms-24-12187-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/fbaabb84d1d5/ijms-24-12187-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/c586a3574a5b/ijms-24-12187-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9594eb6d4ab0/ijms-24-12187-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/8f6d13ddff81/ijms-24-12187-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0e39fe4d7532/ijms-24-12187-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/cc9218802930/ijms-24-12187-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/33018e1ea9b2/ijms-24-12187-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/6ce4a33ded35/ijms-24-12187-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9ceee04b962e/ijms-24-12187-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/5b1d44eda256/ijms-24-12187-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0890d5d36248/ijms-24-12187-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/6bb781cad7a9/ijms-24-12187-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9a6e758e1dd0/ijms-24-12187-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/7a1c09ae7c88/ijms-24-12187-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/0472d42eb3bd/ijms-24-12187-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/78ffdd325fa3/ijms-24-12187-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/7e98c5eee41c/ijms-24-12187-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/bcd7a20d36a4/ijms-24-12187-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/fbaabb84d1d5/ijms-24-12187-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/c586a3574a5b/ijms-24-12187-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5356/10419282/9594eb6d4ab0/ijms-24-12187-g018.jpg

相似文献

1
The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario.整合酶:抗病毒方案中的关键酶概述。
Int J Mol Sci. 2023 Jul 29;24(15):12187. doi: 10.3390/ijms241512187.
2
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors.HIV-1 整合酶四聚体是基于吡啶的变构整合酶抑制剂的抗病毒靶标。
Elife. 2019 May 23;8:e46344. doi: 10.7554/eLife.46344.
3
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.HIV 整合酶的多方面功能及其抑制的治疗策略。
J Biol Chem. 2019 Oct 11;294(41):15137-15157. doi: 10.1074/jbc.REV119.006901. Epub 2019 Aug 29.
4
Advances in the development of HIV integrase strand transfer inhibitors.HIV整合酶链转移抑制剂的研发进展
Eur J Med Chem. 2021 Dec 5;225:113787. doi: 10.1016/j.ejmech.2021.113787. Epub 2021 Aug 18.
5
Discovery and analysis of inhibitors of the human immunodeficiency integrase.人类免疫缺陷病毒整合酶抑制剂的发现与分析
Drug Des Discov. 1997 May;15(1):17-24.
6
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.抗逆转录病毒药物作为1型人类免疫缺陷病毒整合酶和蛋白酶的抑制剂。
J Med Chem. 1996 Jun 21;39(13):2472-81. doi: 10.1021/jm960074e.
7
Allosteric inhibition of HIV-1 integrase activity.变构抑制 HIV-1 整合酶活性。
Curr Opin Chem Biol. 2013 Jun;17(3):339-45. doi: 10.1016/j.cbpa.2013.04.010. Epub 2013 May 3.
8
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.整合酶链转移抑制剂是有效的抗 HIV 药物。
Viruses. 2021 Jan 29;13(2):205. doi: 10.3390/v13020205.
9
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.1H-苄基吲哚衍生物作为新型人类免疫缺陷病毒整合酶链转移抑制剂的临床前评估
Antimicrob Agents Chemother. 2008 Aug;52(8):2861-9. doi: 10.1128/AAC.00210-08. Epub 2008 Jun 9.
10
Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer.取代喹啉 ALLINIs 在 HIV-1 整合酶寡聚体中的优化结合。
J Biol Chem. 2021 Jan-Jun;296:100363. doi: 10.1016/j.jbc.2021.100363. Epub 2021 Feb 2.

引用本文的文献

1
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics.结构病毒学:抗病毒治疗药物研发中的关键决定因素
Viruses. 2025 Mar 14;17(3):417. doi: 10.3390/v17030417.
2
Integrated Computational Analysis of C-2 Substituted Pyrazolopyrimidine and Amide Isosteres ALLINI: 3D-QSAR, Molecular Docking, and ADMET Studies.C-2取代吡唑并嘧啶和酰胺生物电子等排体ALLINI的综合计算分析:3D-QSAR、分子对接和ADMET研究
Curr HIV Res. 2025;23(2):85-98. doi: 10.2174/011570162X360219250206082406.
3
Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.

本文引用的文献

1
Long-acting drugs and formulations for the treatment and prevention of HIV infection.长效药物和制剂,用于治疗和预防 HIV 感染。
Int J Antimicrob Agents. 2021 Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220. Epub 2020 Nov 6.
2
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.HIV 整合酶的多方面功能及其抑制的治疗策略。
J Biol Chem. 2019 Oct 11;294(41):15137-15157. doi: 10.1074/jbc.REV119.006901. Epub 2019 Aug 29.
3
Ultra-long-acting removable drug delivery system for HIV treatment and prevention.
整合酶抑制剂初治的 HIV 感染者中低水平病毒血症的发生率及其对病毒学失败的影响:一项纵向队列研究。
BMC Infect Dis. 2024 Jan 2;24(1):8. doi: 10.1186/s12879-023-08906-5.
长效可移除型 HIV 治疗与预防药物输送系统。
Nat Commun. 2018 Oct 8;9(1):4156. doi: 10.1038/s41467-018-06490-w.
4
HIV drug resistance in low-income and middle-income countries.中低收入国家的 HIV 耐药性。
Lancet HIV. 2018 Oct;5(10):e588-e596. doi: 10.1016/S2352-3018(18)30173-5. Epub 2018 Sep 4.
5
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.卡博特韦在人类免疫缺陷病毒 1 治疗和预防中的应用。
Expert Opin Investig Drugs. 2018 Apr;27(4):413-420. doi: 10.1080/13543784.2018.1460357. Epub 2018 Apr 10.
6
Bictegravir: First Global Approval.比克替拉韦:全球首次批准。
Drugs. 2018 Apr;78(5):601-606. doi: 10.1007/s40265-018-0896-4.
7
Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration.结构功能分析揭示了 HIV-1 整合酶别构抑制剂对病毒成熟和整合的不同影响。
J Biol Chem. 2018 Apr 20;293(16):6172-6186. doi: 10.1074/jbc.M117.816793. Epub 2018 Mar 5.
8
Protein-protein and protein-chromatin interactions of LEDGF/p75 as novel drug targets.LEDGF/p75的蛋白质-蛋白质和蛋白质-染色质相互作用作为新型药物靶点。
Drug Discov Today Technol. 2017 Jun;24:25-31. doi: 10.1016/j.ddtec.2017.11.002. Epub 2017 Nov 23.
9
A safety evaluation of raltegravir for the treatment of HIV.雷特格韦治疗HIV的安全性评估。
Expert Opin Drug Saf. 2018 Feb;17(2):217-223. doi: 10.1080/14740338.2018.1411903. Epub 2017 Dec 5.
10
Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.拉替拉韦每日 1 次片剂:用于治疗人类免疫缺陷病毒 1 型感染的综述。
Drugs. 2017 Oct;77(16):1789-1795. doi: 10.1007/s40265-017-0827-9.